New medicines to fight treatment resistance in breast and lung cancers
Official title: Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11132688 · Data updated 2026-11-12
This project aims to create new medications that can help overcome when breast and lung cancers stop responding to current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | July 12, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $681,912 |
| NIH project number | 5R01CA262530-05 |
| Project ID | NIH-11132688 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational research is for patients with HER2+ breast cancer, triple-negative breast cancer, or KRAS-driven lung cancer who may eventually benefit from new therapies designed to overcome drug resistance.
✕Less likely to help
Patients whose cancers are not HER2+ breast, triple-negative breast, or KRAS-driven lung cancer, or who are not experiencing treatment resistance, may not directly benefit from this specific research.
What this research studies
Many cancer treatments work well at first, but cancer cells can adapt and become resistant over time, making the treatments less effective. This research focuses on developing new drugs that target specific proteins, called CDK12 and CDK13, which cancer cells use to adapt and survive. By blocking these proteins, we hope to make existing therapies work better and for longer. The goal is to find a safe and effective new drug that can be tested in patients with HER2+ breast cancer, triple-negative breast cancer, and KRAS-driven lung cancer that have become resistant to other treatments.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients whose breast or lung cancers have become resistant to current therapies, potentially improving treatment effectiveness and survival.
How similar studies have gone: Other studies have shown that targeting CDK12 and CDK13 is a promising approach to combat acquired drug resistance in cancer.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Duckett, Derek Ronald — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Duckett, Derek Ronald
Related research
Other NIH-funded projects on the same topics.
-
TRIM28 Inhibition for NOTCH2-Mutant Small Cell Lung Cancer
A new approach aims to exploit a weakness in a subset of small cell lung cancer by turning on immune-related signals when NOTCH2 is lost, potentially making tumors more visible to the immune system.
-
Genomic factors shaping lung cancer risk in Native Hawaiians and Pacific Islanders
This NIH grant focuses on understanding why Native Hawaiians, Pacific Islanders, and African Americans have higher lung cancer risk and poorer outcomes by studying tumor DNA and related molecular patterns.
-
PD-L1 PET tracer to guide immune therapy in non-small cell lung cancer
A Johns Hopkins team is testing a Gallium-68 PET tracer to better guide immune checkpoint therapy for people with non-small cell lung cancer.
-
Targeting SMARCA2 to treat lung cancers that lack SMARCA4
This work looks at whether blocking a protein called SMARCA2 can slow or stop lung cancers that have lost the related gene SMARCA4.
-
New medicines for lung cancers caused by KRAS or BRAF changes
Testing new medicines that block ERK/RAF signaling in people with lung cancer driven by KRAS or BRAF mutations.
-
Understanding lung cancer risks in Native Hawaiians
This research looks at the genetic differences in lung cancer among Native Hawaiians to better understand why they face higher risks and poorer outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.